143 related articles for article (PubMed ID: 27160228)
41. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
42. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
[TBL] [Abstract][Full Text] [Related]
43. Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.
Knepper TC; Freeman ML; Gibney GT; McLeod HL; Russell JS
JAMA Dermatol; 2017 Jun; 153(6):607-609. PubMed ID: 28384659
[No Abstract] [Full Text] [Related]
44. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.
Deng Y; Sychterz C; Suttle AB; Dar MM; Bershas D; Negash K; Qian Y; Chen EP; Gorycki PD; Ho MY
Xenobiotica; 2013 May; 43(5):443-53. PubMed ID: 23548165
[TBL] [Abstract][Full Text] [Related]
45. Irradiation-induced angiosarcoma and anti-angiogenic therapy: a therapeutic hope?
Azzariti A; Porcelli L; Mangia A; Saponaro C; Quatrale AE; Popescu OS; Strippoli S; Simone G; Paradiso A; Guida M
Exp Cell Res; 2014 Feb; 321(2):240-7. PubMed ID: 24384475
[TBL] [Abstract][Full Text] [Related]
46. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
[TBL] [Abstract][Full Text] [Related]
47. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
48. Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report.
De Sanctis R; Lorenzi E; Agostinetto E; D'Amico T; Simonelli M; Santoro A
Medicine (Baltimore); 2019 Dec; 98(50):e18089. PubMed ID: 31852067
[TBL] [Abstract][Full Text] [Related]
49. Pazopanib as a potential chemotherapy for cutaneous angiosarcoma: A case series of 10 patients from a single institution.
Fujiwara S; Nakano E; Nakamura K; Washio K; Ogura K; Nishigori C
J Dermatol; 2020 Jul; 47(7):e273-e274. PubMed ID: 32399986
[No Abstract] [Full Text] [Related]
50. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
[TBL] [Abstract][Full Text] [Related]
51. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
[TBL] [Abstract][Full Text] [Related]
52. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
Altorki N; Lane ME; Bauer T; Lee PC; Guarino MJ; Pass H; Felip E; Peylan-Ramu N; Gurpide A; Grannis FW; Mitchell JD; Tachdjian S; Swann RS; Huff A; Roychowdhury DF; Reeves A; Ottesen LH; Yankelevitz DF
J Clin Oncol; 2010 Jul; 28(19):3131-7. PubMed ID: 20516450
[TBL] [Abstract][Full Text] [Related]
53. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
Bupathi M; Hays JL; Chen JL
PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
[TBL] [Abstract][Full Text] [Related]
54. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
Grassi P; Verzoni E; Ratta R; Porcu L; Prisciandaro M; Mennitto A; Calareso G; de Braud F; Procopio G
Drugs R D; 2017 Sep; 17(3):461-467. PubMed ID: 28801802
[TBL] [Abstract][Full Text] [Related]
55. Preoperative Treatment With Pazopanib in a Case of Chemotherapy-Resistant Infantile Fibrosarcoma.
Yanagisawa R; Noguchi M; Fujita K; Sakashita K; Sano K; Ogiso Y; Katsuyama Y; Kondo Y; Komori K; Fujihara I; Kitamura R; Hiroma T; Nakamura T
Pediatr Blood Cancer; 2016 Feb; 63(2):348-51. PubMed ID: 26375879
[TBL] [Abstract][Full Text] [Related]
56. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
Tan AR; Gibbon DG; Stein MN; Lindquist D; Edenfield JW; Martin JC; Gregory C; Suttle AB; Tada H; Botbyl J; Stephenson JJ
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1635-43. PubMed ID: 23636448
[TBL] [Abstract][Full Text] [Related]
57. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Podar K; Tonon G; Sattler M; Tai YT; Legouill S; Yasui H; Ishitsuka K; Kumar S; Kumar R; Pandite LN; Hideshima T; Chauhan D; Anderson KC
Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19478-83. PubMed ID: 17164332
[TBL] [Abstract][Full Text] [Related]
58. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
59. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Yildiz C; Kacan T; Akkar OB; Karakus S; Kacan SB; Ozer H; Cetin A
Reprod Sci; 2015 Nov; 22(11):1445-51. PubMed ID: 25963915
[TBL] [Abstract][Full Text] [Related]
60. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
Sloan B; Scheinfeld NS
Curr Opin Investig Drugs; 2008 Dec; 9(12):1324-35. PubMed ID: 19037839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]